ArticleDiscover oncology2025
Identification of immunoheterogeneous key prognostic protein ZC3H12D in OSCC and analysis of prognostic models and drug resistance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe constructed a nomogram model utilizing key clinical and molecular biological variables to predict the 1-year, 3-year, and 5-year survival probabilities for patients with oral squamous cell carcinoma (OSCC). The model's predictive efficacy was assessed through calibration curves. Additionally, a detailed Spearman correlation analysis of the ZC3H12D gene was executed, with patient data stratified into high and low expression categories based on its expression levels for differential gene analysis. Following this, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, as well as Gene Set Enrichment Analysis (GSEA), were performed on the identified differentially expressed genes to delineate their specific contributions to biological processes and metabolic pathways.
resultsThe nomogram model demonstrated a high degree of predictive accuracy, effectively predicting the survival probabilities of oral cancer. patientsThe correlation analysis of the ZC3H12D gene revealed significant correlations with various immune cell types. A total of 439 significantly differentially expressed genes were identified through differential gene analysis. GO and KEGG enrichment analyses, along with GSEA analysis, further elucidated the specific roles of these differentially expressed genes in biological processes and metabolic pathways. Moreover, immune infiltration analysis indicated significant differences between the high and low expression groups of ZC3H12D in terms of immune cell infiltration, immune scores, and ESTIMATE scores.
conclusionThe nomogram model constructed in this study provides a practical tool for prognostic assessment in OSCC patients. Additionally, the in-depth analysis of the ZC3H12D gene reveals its significant role in the occurrence and development of oral cancer, providing data support and a theoretical basis for further research.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.